(ORKA) Oruka Therapeutics - Overview
Stock: Monoclonal Antibody, Interleukin-23, Interleukin-17, Psoriasis, Clinical
| Risk 5d forecast | |
|---|---|
| Volatility | 80.0% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.54 |
| Alpha | 114.54 |
| Character TTM | |
|---|---|
| Beta | 1.095 |
| Beta Downside | 1.036 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.76% |
| CAGR/Max DD | 0.46 |
Description: ORKA Oruka Therapeutics December 24, 2025
Oruka Therapeutics (NASDAQ: ORKA) is a clinical-stage biotech headquartered in Menlo Park, CA, developing monoclonal antibodies for psoriasis and broader inflammatory-immunology indications. Its pipeline includes ORKA-001 (IL-23 p19 inhibitor) in a Phase 1 trial, ORKA-002 (dual IL-17A/F blocker) targeting psoriasis, psoriatic arthritis and other diseases, ORKA-003 (undisclosed target), and ORKA-021, a planned sequential combination of ORKA-001 and ORKA-002.
Key sector context: the global psoriasis biologics market was ≈ $13 bn in 2023 and is projected to grow ~6 % CAGR, driven by expanding patient access and premium pricing. Oruka’s focus on IL-23 and IL-17 pathways aligns with the two largest therapeutic classes in this market, but it faces entrenched competitors such as AbbVie (Skyrizi) and Eli Lilly (Taltz), which together hold > 30 % market share.
Financial snapshot (as of the latest 10-Q): cash and cash equivalents ≈ $55 m, with a monthly burn rate of roughly $5 m, giving a runway of ~11 months absent additional financing. The company’s R&D spend has risen 42 % YoY, reflecting the initiation of Phase 1 studies for ORKA-001 and pre-clinical work on ORKA-003.
For a deeper quantitative comparison, the ValueRay platform provides a data-driven framework to assess ORKA’s valuation relative to peers.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.17 > 0.02 and ΔFCF/TA -6.44 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.17 > 3% & CFO -84.4m > Net Income -109.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.1m) vs 12m ago 193.5% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -77.18 > 6 (EBITDA TTM -113.2m / Interest Expense TTM 1.47m) |
Altman Z'' -5.81
| A: 0.66 (Total Current Assets 355.2m - Total Current Liabilities 21.0m) / Total Assets 509.3m |
| B: -0.31 (Retained Earnings -159.6m / Total Assets 509.3m) |
| C: -0.25 (EBIT TTM -113.3m / Avg Total Assets 461.7m) |
| D: -7.09 (Book Value of Equity -159.3m / Total Liabilities 22.5m) |
| Altman-Z'' Score: -5.81 = D |
What is the price of ORKA shares?
Over the past week, the price has changed by -3.45%, over one month by +24.15%, over three months by +16.87% and over the past year by +152.68%.
Is ORKA a buy, sell or hold?
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ORKA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55.7 | 68.4% |
| Analysts Target Price | 55.7 | 68.4% |
| ValueRay Target Price | 35.5 | 7.5% |
ORKA Fundamental Data Overview February 07, 2026
EBIT TTM = -113.3m USD
EBITDA TTM = -113.2m USD
Long Term Debt = 1.91m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 419.0k USD (from shortTermDebt, last quarter)
Debt = 1.91m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.17b USD (1.52b + Debt 1.91m - CCE 349.2m)
Interest Coverage Ratio = -77.18 (Ebit TTM -113.3m / Interest Expense TTM 1.47m)
EV/FCF = -13.87x (Enterprise Value 1.17b / FCF TTM -84.6m)
FCF Yield = -7.21% (FCF TTM -84.6m / Enterprise Value 1.17b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 51.0k) / Revenue TTM)
Tobins Q-Ratio = 2.30 (Enterprise Value 1.17b / Total Assets 509.3m)
Interest Expense / Debt = 76.78% (Interest Expense 1.47m / Debt 1.91m)
Taxrate = 21.0% (US default 21%)
NOPAT = -89.5m (EBIT -113.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 16.94 (Total Current Assets 355.2m / Total Current Liabilities 21.0m)
Debt / Equity = 0.00 (Debt 1.91m / totalStockholderEquity, last quarter 486.8m)
Debt / EBITDA = 0.79 (negative EBITDA) (Net Debt -89.3m / EBITDA -113.2m)
Debt / FCF = 1.06 (negative FCF - burning cash) (Net Debt -89.3m / FCF TTM -84.6m)
Total Stockholder Equity = 394.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.66% (Net Income -109.2m / Total Assets 509.3m)
RoE = -27.70% (Net Income TTM -109.2m / Total Stockholder Equity 394.3m)
RoCE = -28.59% (EBIT -113.3m / Capital Employed (Equity 394.3m + L.T.Debt 1.91m))
RoIC = -22.87% (negative operating profit) (NOPAT -89.5m / Invested Capital 391.4m)
WACC = 9.94% (E(1.52b)/V(1.52b) * Re(9.95%) + (debt cost/tax rate unavailable))
Discount Rate = 9.95% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 74.84%
Fair Price DCF = unknown (Cash Flow -84.6m)
EPS Correlation: -31.75 | EPS CAGR: -2.24% | SUE: 0.01 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.62 | Chg30d=+0.014 | Revisions Net=+0 | Analysts=6
EPS next Year (2026-12-31): EPS=-2.39 | Chg30d=+0.013 | Revisions Net=-1 | Growth EPS=-15.8% | Growth Revenue=+0.0%